Overview

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

Status:
Completed

Trial end date:
2013-11-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to see if Gleevec, known as imatinib mesylate (STI571), can improve the disease condition in patients with hypereosinophilic syndrome, polycythemia vera, atypical CML or CMML with PDGF-R fusion genes, or mastocytosis.

Phase:

N/A

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Novartis Pharmaceuticals

Treatments:

Imatinib Mesylate